Central Venous Catheter-related Infections (CRI) in Hematology and Oncology

Recommendations from the society for diagnosis and therapy of haematological and oncological diseases
The information of the DGHO Onkopedia Web Site is not intended or implied to be a substitute for professional medical advice or medical care. The advice of a medical professional should always be sought prior to commencing any form of medical treatment. To this end, all component information contained within the web site is done so for solely educational purposes. DGHO Deutsche Gesellschaft für Hämatologie und Onkologie and all of its staff, agents and members disclaim any and all warranties and representations with regards to the information contained on the DGHO Web Site. This includes any implied warranties and conditions that may be derived from the aforementioned web site information.
Table of contents

1 Definition and Basic Information ............................................ 2
2 Prevention of Catheter-Related Infections ............................ 2
3 Diagnosis ................................................................................ 3
   3.1 Diagnostic Criteria ................................................................. 3
   3.2 Diagnostics ........................................................................ 3
4 Therapy .................................................................................. 4
   4.1 Antimicrobial Therapy ............................................................ 4
   4.2 Management of CVC ............................................................... 4
5 References ............................................................................... 5
6 Links ....................................................................................... 5
8 Authors’ Affiliations ................................................................. 5
9 Disclosure ............................................................................... 7
Central Venous Catheter-related Infections (CRI) in Hematology and Oncology

Date of document: January 2012

Compliance rules:
- Guideline
- Conflict of interests

Authors: Hans-Heinrich Wolf, Malte Leithäuser, Georg Maschmeyer, Hans-Jürgen Salwender, Ulrike Klein, Iris Chaberny, Florian Weißinger, Dieter Buchheidt, Markus Ruhnke, Gerlinde Egerer, Oliver A. Cornely, Gerd Fätkenheuer, Sabine Mousset

on behalf of the AGIHO Infectious Diseases Working Party of the DGHO

1 Definition and Basic Information

Insertion of central venous catheters is a common procedure in the treatment of patients with hematologic malignancies and solid tumors. Catheter-related infections (CRI) cause considerable morbidity. They are also one of the differential diagnoses of fever of unknown origin in neutropenic patients. This guideline on diagnostics and therapy of CRI was developed by the AGIHO Infectious Diseases Working Party of the DGHO.

Categories are based on the evaluation of study results and the recommendations developed by the Infectious Diseases Society of America, ISDA, see Table 1.

Table 1: Categories of Evidence

<table>
<thead>
<tr>
<th>Category, grade Strength of Recommendation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Good evidence to support a recommendation for use</td>
</tr>
<tr>
<td>B</td>
<td>Moderate evidence to support a recommendation for use</td>
</tr>
<tr>
<td>C</td>
<td>Poor evidence to support a recommendation for use</td>
</tr>
<tr>
<td>D</td>
<td>Moderate evidence to support a recommendation against use</td>
</tr>
<tr>
<td>E</td>
<td>Good evidence to support a recommendation against use</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Quality of Evidence</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Evidence from ≥ 1 properly randomized, controlled trial</td>
</tr>
<tr>
<td>II</td>
<td>Evidence from ≥ 1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferable from &gt; 1 centre); from multiple time series; or from dramatic results of uncontrolled experiments</td>
</tr>
<tr>
<td>III</td>
<td>Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports from expert committees</td>
</tr>
</tbody>
</table>

2 Prevention of Catheter-Related Infections

Recommendations are summarized in Table 2.
Table 2: Prevention of Catheter-Related Infections

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Category of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Access via the subclavian vein is associated with a lower CRI rate as compared to internal jugular vein</td>
<td>A-I</td>
</tr>
<tr>
<td>Compliance with hygiene principles during insertion and standardized aseptic placement help to avoid infections</td>
<td>A-I</td>
</tr>
<tr>
<td>Impregnation of CVCs with antiseptics (chlorhexidine/silver sulfadiazine) or antibiotics (minocycline/ rifampicin) reduces incidence of catheter colonization</td>
<td>A-I</td>
</tr>
<tr>
<td>Education programs for nurses and physicians help to reduce the incidence of CRI</td>
<td>A-II</td>
</tr>
<tr>
<td>Ultrasound-guided placement helps to reduce CRI rates</td>
<td>B-I</td>
</tr>
<tr>
<td>Alcoholic chlorhexidine solution, alcoholic polyvidone-iodine solutions or 70% propanolol should be used for disinfection of the catheter insertion site</td>
<td>A-I</td>
</tr>
<tr>
<td>More frequent replacement does not reduce the incidence of infection</td>
<td>D-I</td>
</tr>
<tr>
<td>Systemic prophylactic antibiotic treatment prior to catheter insertion is not recommended</td>
<td>E-I</td>
</tr>
<tr>
<td>Topical application of antibiotic ointments for reducing staphylococcal colonization at the catheter insertion site and as a nasal ointment is not recommended</td>
<td>E-I</td>
</tr>
</tbody>
</table>

3 Diagnosis

3.1 Diagnostic Criteria

In clinical practice, diagnosis of central venous catheter-related infections is based on symptoms and test results not always withstanding strict definitions. In many cases, CRI can only be presumed backed-up by clinical symptoms and test results listed in Table 3.

Table 3: Diagnostic Criteria for CRI

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Criteria</th>
</tr>
</thead>
</table>
| **Definite CRI** | • Pathogen detected at the catheter tip by a standard method plus same pathogen with the same susceptibility pattern detected in blood culture  
and / or  
• DTTP\(^1\) > 2 h  
and / or  
• CFU Ratio\(^2\) ≥ 10 |
| **Probable CRI** | • Local infection at the insertion site  
and / or  
• Remission of previously refractory fever within 48h after catheter removal plus positive blood culture  
and / or  
• Colonization of the catheter tip\(^3\) |
| **Possible CRI** | • Pathogen detected in blood culture that is typically implicated in causing catheter infections (S. epidermidis, S. aureus or other coagulase – negative Staphylococci, Candida spp.)  
and / or  
• Positive blood culture and no other focus identified in a patient with an indwelling central venous catheter (CVC) |

Legend:
\(^1\) DTTP (Differential Time To Positivity) – Difference in time between positivity of results of catheter culture and peripheral blood culture;  
\(^2\) CFU Ratio – Ratio of Colony Forming Units between pathogen detected in quantitative catheter and peripheral blood cultures;  
\(^3\) Results above the limit specified for the method

3.2 Diagnostics

Recommendations are summarized in Table 4.
Table 4: Diagnostics of Central Venous CRIs

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Category of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>One pair of blood cultures (aerobic and anaerobic) to be taken from the catheter and one from a peripheral vein for microbiological evaluation</td>
<td>A-II</td>
</tr>
<tr>
<td>DTTP(^1) for routine diagnostic purposes</td>
<td>A-I</td>
</tr>
<tr>
<td>Semiquantitative culturing for microbiological diagnosis of CRI after catheter removal</td>
<td>A-II</td>
</tr>
<tr>
<td>Quantitative culturing from the interior surface of the catheter, vortex and ultrasound treatment of the catheter to disengage adhesive bacteria</td>
<td>A-II</td>
</tr>
<tr>
<td>Endoluminal brushing if blood cultures cannot be drawn via CVC line</td>
<td>C-II</td>
</tr>
<tr>
<td>Ultrasound imaging along the catheter tunnel for diagnosis of CRI</td>
<td>C-III</td>
</tr>
<tr>
<td>Blood cultures from all lumina of the catheter</td>
<td>C-III</td>
</tr>
<tr>
<td>No cultures from the catheter hub</td>
<td>D-II</td>
</tr>
<tr>
<td>No skin swab for diagnosis of CRI</td>
<td>D-II</td>
</tr>
<tr>
<td>No placing of the catheter tip in broth and subsequently culturing the pathogen</td>
<td>E-II</td>
</tr>
</tbody>
</table>

Legend:
\(^1\) DTTP (Differential Time To Positivity) – Difference in time between positivity of results of catheter culture and peripheral blood culture;

4 Therapy

First goal is the successful treatment of CRI using systemic antimicrobial therapy. Second goal is the prevention of secondary infection.

4.1 Antimicrobial Therapy

Recommendations are summarized in Table 5.

Table 5: Antimicrobial Therapy in CRI

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Category of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimicrobial treatment of suspected CRI based on the same principles as treatment of fever of unknown origin (FUO)</td>
<td></td>
</tr>
<tr>
<td>Prompt empirical vancomycin therapy is not required</td>
<td>A-II</td>
</tr>
<tr>
<td>At least 2 weeks of systemic antimicrobial treatment in immunosuppressed patients</td>
<td>B-III</td>
</tr>
<tr>
<td>For in vitro susceptible pathogens, therapy with a penicillinase-resistant penicillin is more effective and, therefore, preferable to treatment with glycopeptide antibiotics</td>
<td>B-II</td>
</tr>
<tr>
<td>Antibiotic lock in addition to systemic antibiotic therapy has shown to reduce the relapse rate of CRI</td>
<td>C-III</td>
</tr>
</tbody>
</table>

4.2 Management of CVC

Recommendations are summarized in Table 6.
Table 6: Management of CVC

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Category of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary catheter removal is necessary in</td>
<td></td>
</tr>
<tr>
<td>• CRI due to <em>Staphylococcus aureus</em></td>
<td>A-II</td>
</tr>
<tr>
<td>• CRI due to <em>Candida</em> spp.</td>
<td>B-II</td>
</tr>
<tr>
<td>• Tunnel or pocket infection</td>
<td>B-III</td>
</tr>
<tr>
<td>• Complicated CRI (e.g. metastatic organ or severe soft tissue infections)</td>
<td>B-II</td>
</tr>
<tr>
<td>Preservation of CVC may be initially attempted in clinically stable patients</td>
<td></td>
</tr>
<tr>
<td>in the presence of the following pathogens</td>
<td></td>
</tr>
<tr>
<td>• Coagulase-negative <em>Staphylococci</em></td>
<td>B-III</td>
</tr>
<tr>
<td>• <em>Corynebacterium jeikeium</em></td>
<td></td>
</tr>
<tr>
<td>• <em>Acinetobacter baumannii</em></td>
<td></td>
</tr>
<tr>
<td>• <em>Stenotrophomonas maltophilia</em></td>
<td></td>
</tr>
<tr>
<td>• <em>Pseudomonas aeruginosa</em></td>
<td></td>
</tr>
<tr>
<td>• <em>Bacillus</em> spp.</td>
<td></td>
</tr>
</tbody>
</table>

5 References


7 Links

https://www.agiho.de/ueber-die-agiho

8 Authors’ Affiliations

**Dr. med. Hans-Heinrich Wolf**  
Südharzklinikum  
Klinik für Innere Medizin III  
Hämatologie, Onkologie, Hämostaseologie  
Dr.-Robert-Koch-Str. 39  
99734 Nordhausen  
Hans.Wolf@shk-ndh.de

**Dr. med. Malte Leithäuser**  
Gemeinschaftspraxis  
Lakner/Decker/Leithäuser  
Wismarische Str. 32  
18057 Rostock  
mleith@gmx.de

**Prof. Dr. med. Georg Maschmeyer**  
Klinikum Ernst von Bergmann  
Zentrum für Innere Medizin  
Klinik für Hämatologie, Onkologie und Palliativmedizin  
Charlottenstr. 72  
14467 Potsdam  
georg.maschmeyer@klinikumevb.de
Dr. med. Hans-Jürgen Salwender
Asklepios Klinik Hamburg-Altona
II. Medizinische Abteilung
Hämatologie / Stammzelltransplantation
Paul-Ehrlich-Str. 1
22763 Hamburg
h.salwender@asklepios.com

Dr. med. Ulrike Klein
Universitätsklinikum Heidelberg
Kaufmännische Leitung UFHK und ZKJM
Im Neuenheimer Feld 430
69120 Heidelberg
Ulrike.Klein2@med.uni-heidelberg.de

Prof. Dr. med. Iris Chaberny
Universitätsklinikum Leipzig AöR
Institut für Hygiene / Krankenhaushygiene
Johannesallee 34, Haus L
04103 Leipzig
Iris.Chaberny@medizin.uni-leipzig.de

Prof. Dr. med. Florian Weißinger
Evangelisches Klinikum Bethel gGmbH
Johannesstift
Klinik für Innere Medizin, Hämatologie/Onkologie und Palliativmedizin
Schildescher Str. 99
33611 Bielefeld
florian.weissinger@evkb.de

Prof. Dr. med. Dieter Buchheidt
Klinikum Mannheim GmbH
Medizinische Fakultät Mannheim
III. Medizinische Klinik
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
dieter.buchheidt@umm.de

Prof. Dr. med. Markus Ruhnke
Helios Klinikum Aue
Klinik für Hämatologie/Onkologie und Palliativmedizin
Gartenstr. 6
08280 Aue
Markus.Ruhnke@helios-gesundheit.de

Prof. Dr. med. Gerlinde Egerer
Universitätsklinikum Heidelberg
Medizinische Klinik V
Hämatologie/Onkologie
Im Neuenheimer Feld 410
69120 Heidelberg
gerlinde.egerer@med.uni-heidelberg.de
**Prof. Dr. med. Oliver A. Cornely**
Uniklinik Köln, Klinik I für Innere Med.
Zentrum für Klinische Studien
Infektiologie-Hämatologie-Onkologie
Kerpener Str. 62
50937 Köln
oliver.cornely@uk-koeln.de

**Prof. Dr. med. Gerd Fätkenheuer**
Universität zu Köln
I. Medizinische Klinik
Joseph-Stelzmann-Str. 9
50924 Köln
G.Faetkenheuer@uni-koeln.de

**Dr. Sabine Mousset**
St. Josefs Hospital
Medizinische Klinik III
Palliativmedizin / Onkologie
Beethovenstr. 20
65189 Wiesbaden
smousset@joho.de

9 Disclosure

according to the rules of the German Association of Hematology and Oncology (DGHO, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie) and the recommendations of the AWMF (version dated April 23, 2010) and international recommendations.